For US Healthcare Professionals Only
TRAVATAN Z® EFFICACY

For patients with open-angle
glaucoma or ocular hypertension

TRAVATAN Z® SOLUTION DEMONSTRATED SIGNIFICANTLY LOWER MEAN IOP1

Patients were able to lower their mean IOP by up to 8.5 mm Hg from baseline1

Week 2

8 AM

-8.5

10 AM

-7.8

4 PM

-7.5

Week 6

8 AM

-8.3

10 AM

-7.7

4 PM

-7.5

Month 3

8 AM

-8.3

10 AM

-7.8

4 PM

-7.4

Study Design: Double-masked, randomized, parallel-group, multicenter noninferiority comparison of the efficacy and safety of travoprost 0.004% preserved with benzalkonium chloride (BAK) and TRAVATAN Z® Solution after 3 months of treatment in patients with open-angle glaucoma or ocular hypertension. Mean baseline IOPs were 27.0 mm Hg (n=322), 25.5 mm Hg (n=322), and 24.8 mm Hg (n=322) at 8 AM, 10 AM, and 4 PM for TRAVATAN Z® Solution. At the end of Month 3, the TRAVATAN Z® Solution group had mean IOPs (95% Cl for the treatment differences) of 18.7 mm Hg (–0.4, 0.5), 17.7 mm Hg (–0.4, 0.6), and 17.4 mm Hg (–0.2, 0.8) at 8 AM, 10 AM, and 4 PM, respectively. Statistically equivalent reductions in IOP (95% Cls for the treatment differences were entirely within ± mm Hg) were demonstrated between the treatments at all study visits during the 3 months of treatment.1

For patients with open-angle
glaucoma or ocular hypertension

TRAVATAN Z® SOLUTION DEMONSTRATED SIGNIFICANT AND SUSTAINED IOP LOWERING1

TRAVATAN Z® Solution achieved up to 30% sustained lowering at 12, 14, and 20 hours postdose in a 3-month study1,4

Week 2

8 AM
(n=320)

31.3%

10 AM
(n=320)

30.4%

4 PM
(n=319)

30.0%

Week 6

8 AM
(n=313)

30.5%

10 AM
(n=313)

29.9%

4 PM
(n=309)

30.0%

Month 3

8 AM
(n=309)

30.9%

10 AM
(n=308)

30.2%

4 PM
(n=310)

29.8%

Study Time Points (Post-8 PM Dose)

Study Design: Double-masked, randomized, parallel-group, multicenter noninferiority comparison of the efficacy and safety of travoprost 0.004% preserved with benzalkonium chloride (BAK) and TRAVATAN Z® Solution after 3 months of treatment in patients with open-angle glaucoma or ocular hypertension. Mean baseline IOPs were 27.0 mm Hg (n=322), 25.5 mm Hg (n=322), and 24.8 mm Hg (n=322) at 8 AM, 10 AM, and 4 PM for TRAVATAN Z® Solution. At the end of Month 3, the TRAVATAN Z® Solution group had mean IOPs (95% Cl for the treatment differences) of 18.7 mm Hg (–0.4, 0.5), 17.7 mm Hg (–0.4, 0.6), and 17.4 mm Hg (–0.2, 0.8) at 8 AM, 10 AM, and 4 PM, respectively. Statistically equivalent reductions in IOP (95% Cls for the treatment differences were entirely within ± mm Hg) were demonstrated between the treatments at all study visits during the 3 months of treatment.1

TRAVATAN Z® MECHANISM OF ACTION

Travoprost free acid, a prostaglandin, is a selective FP prostanoid receptor agonist

WHICH IS BELIEVED TO REDUCE INTRAOCULAR PRESSURE BY INCREASING UVEOSCLERAL
OUTFLOW2

The exact mechanism of action (MOA) is unknown at this time.2

Travoprost acid is a selective FP receptor analog, exhibiting a high affinity for the FP receptor and minimal affinity for PG receptors.5

FP=Prostaglandin F; PG=Prostaglandin.

TRAVATAN Z® SAFETY AND ADVERSE REACTIONS

Are you concerned with patients wanting to discontinue therapy?

ONLY 3% OF PATIENTS DISCONTINUED USE DUE TO CONJUNCTIVAL HYPEREMIA2

TRAVATAN Z® Solution has an established safety profile.2

% of Patients in Clinical Studies Adverse
 Reaction
30-50% Ocular hyperemia
Up to 3% Discontinued therapy due to conjunctival hyperemia
5-10% Decreased visual acuity, eye discomfort, foreign body sensation, pain, pruritus
1-4% Abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, corneal staining, dry eye, iris discoloration, keratitis, lid margin crusting, ocular inflammation, photophobia, subconjunctival hemorrhage, tearing

Additional adverse reactions have been identified during post approval use of TRAVATAN® or TRAVATAN Z® in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to TRAVATAN® or TRAVATAN Z®, or a combination of these factors, include: arrhythmia, vomiting, epistaxis, tachycardia, and insomnia. In postmarketing use with prostaglandin analogs, periorbital and lid changes including deepening of the eyelid sulcus have been observed.2

PATIENT RESOURCES

Novartis offers a co-pay card to help patients save on the cost of TRAVATAN Z® eye drops.

CO-PAY SAVINGS

Your eligible, commercially insured patients may pay as little as $30* for a 30-, 60-, or 90-day supply.

$30

Eligible commercially insured patients may pay as little as $30 in out-of-pocket expenses per product with a maximum benefit per product of $2,000 per calendar year.

Over 90% of lives are covered
nationally
on Part D and commercial insurance plans.3

OPENINGS® PATIENT SUPPORT PROGRAM

  • Educational materials — to help patients learn about their treatment and care with TRAVATAN Z® Solution
  • Active communications — provide ongoing emails with valuable suggestions, updates, and insights
  • Tools to help manage treatment — including refill reminders and tips for mistake-proof dosing
  • Active communications — provide ongoing emails with valuable suggestions, updates, and insights
  • For more information, please visit www.openingsprogram.com

*TRAVATAN Z® Solution Co-Pay Card Terms & Conditions
Limitations apply. Valid only for those with private insurance. The TRAVATAN Z® Solution Co-Pay Card includes the Co-Pay Card, Payment Card (if applicable), and Rebate. Eligible commercially insured patients may pay as little as $30 in out‑of‑pocket expenses for TRAVATAN Z® Solution with a maximum of $2,000 per calendar year. Patients must be 16 years or older to be eligible. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, or (iii) where the patient’s insurance plan reimburses for the entire cost of the drug. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

Search results for ''

    INDICATIONS AND USAGE

    TRAVATAN Z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

    Dosage and Administration

    The recommended dosage is one drop in the affected eye(s) once daily in the evening. TRAVATAN Z® Solution should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP lowering effect.

    TRAVATAN Z® Solution may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

    IMPORTANT SAFETY INFORMATION

    Warnings and Precautions

    Pigmentation – Travoprost ophthalmic solution has been reported to increase the pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as travoprost is administered. After discontinuation of travoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. The long-term effects of increased pigmentation are not known. While treatment with TRAVATAN Z® Solution can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

    Eyelash Changes – TRAVATAN Z® Solution may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.

    Intraocular Inflammation – TRAVATAN Z® Solution should be used with caution in patients with active intraocular inflammation (e.g. uveitis) because the inflammation may be exacerbated.

    Macular Edema – Macular edema, including cystoid macular edema, has been reported during treatment with travoprost ophthalmic solution. TRAVATAN Z® Solution should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

    Angle-closure, Inflammatory or Neovascular Glaucoma – TRAVATAN Z® Solution has not been evaluated for the treatment of angle-closure, inflammatory, or neovascular glaucoma.

    Bacterial Keratitis – There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

    Use with Contact Lenses – Contact lenses should be removed prior to instillation of TRAVATAN Z® Solution and may be reinserted 15 minutes following its administration.

    Adverse Reactions

    The most common adverse reaction observed in controlled clinical trials with TRAVATAN® (travoprost ophthalmic solution) 0.004% and TRAVATAN Z® Solution was ocular hyperemia, which was reported in 30% to 50% of patients. Up to 3% of patients discontinued therapy due to conjunctival hyperemia. Ocular adverse reactions reported at an incidence of 5% to 10% in these clinical trials included decreased visual acuity, eye discomfort, foreign body sensation, pain, and pruritus.

    Additional adverse reactions have been identified during post approval use of TRAVATAN® or TRAVATAN Z® in clinical practice. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to TRAVATAN® or TRAVATAN Z®, or a combination of these factors, include: arrhythmia, vomiting, epistaxis, tachycardia, and insomnia. In postmarketing use with prostaglandin analogs, periorbital and lid changes including deepening of the eyelid sulcus have been observed.

    Use in Specific Populations

    Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

    For additional information on TRAVATAN Z® Solution, click here for full Prescribing Information.

    References: 1. Lewis RA, Katz GJ, Weiss MJ, et al; for Travoprost BAC-free Study Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16(1):98-103. 2. TRAVATAN Z® Solution Prescribing Information. Fort Worth, TX: Alcon Laboratories, Inc. 2017. 3. Fingertip Formulary, (estimate derived from information used under license from Fingertip Formulary, LLC, which expressly reserves all rights, including rights of copying, distribution, and republication) 2018. 4. Data on file. Novartis Alcon Laboratories, Inc; 2005. 5. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19(6):501-515.

    SHARE